CalcMyPeptide
Khavinson BioregulatorAlso known as: Retinal bioregulator

Retinalamin

Retinalamin is a heavily regulated, organ-specific Cytomax polypeptide fraction extracted exclusively from youthful retinal tissue. Standing as a fully approved pharmaceutical intervention, it is delivered via direct parabulbar injection (next to the eye). It is the ultimate clinical spearhead used to aggressively halt blindness stemming from severe diabetic retinopathy, fiercely combat Age-Related Macular Degeneration (AMD), and preserve fading vision in retinitis pigmentosa.

Reviewed by CalcMyPeptide Editorial Team
Last updated: April 2026Evidence: Moderate1 peer-reviewed citation

Quick Stats

Half-LifeMixture (variable)
Dose Range5 mg IM or parabulbar injection
Frequency1× daily for 10 days
Vial Sizes5 mg
BioavailabilityIntramuscular or parabulbar injection
Year Developed1999

Scientific Data

Molecular Formula
Polypeptide extract (Retinal tissue)
Molecular Weight
Mixture (<10 kDa)
PubChem ID

Mechanism of Action

Retinalamin is a highly purified, clinical-grade polypeptide extract derived from the retina tissues of cattle or pigs. It is an approved prescription pharmaceutical in Russia used primarily in ophthalmology.

Retinalamin works by restoring impaired cellular metabolism in the retina. It stimulates photoreceptor division, improves the function of the retinal pigment epithelium (RPE), reduces vascular permeability, and prevents the death (apoptosis) of retinal cells during ischemic or degenerative states. It is heavily utilized for treating diabetic retinopathy, central retinal vein occlusion, and primary open-angle glaucoma.

Source: PMID: 15677927

Background & History

Retinalamin is a specialized ophthalmological Cytomax extract developed at the Saint Petersburg Institute of Bioregulation and Gerontology. It is one of the few Khavinson preparations administered via the parabulbar route (injection into periocular fat), allowing more direct access to retinal tissues. Used clinically in Russia for degenerative retinal conditions, it represents the application of peptide bioregulation to ophthalmology.

Research Use Cases

  • Age-related macular degeneration
  • Diabetic retinopathy
  • Retinitis pigmentosa
  • Glaucoma support

Dosing Protocol

Typical Dose5 mg IM or parabulbar injection
Frequency1× daily for 10 days
Half-Life~2 hours
Common Vial Sizes5 mg

Dosing Protocols

Clinical Protocol

Dose
5 mg
Frequency
Daily IM or Parabulbar injection for 10 days
Note: Usually administered by an ophthalmologist (parabulbar = injected into the tissue adjacent to the eyeball).

Body-Weight Dosing Reference

Estimated doses extrapolated from the published research range of 50005000 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.

WeightLowTargetHigh
120 lb(54 kg)3857 mcg3857 mcg3857 mcg
140 lb(63 kg)4500 mcg4500 mcg4500 mcg
160 lb(73 kg)5214 mcg5214 mcg5214 mcg
180 lb(82 kg)5857 mcg5857 mcg5857 mcg
200 lb(91 kg)6500 mcg6500 mcg6500 mcg
220 lb(100 kg)7143 mcg7143 mcg7143 mcg
250 lb(113 kg)8071 mcg8071 mcg8071 mcg

💉 For exact syringe units based on your vial concentration, use the Retinalamin Reconstitution Calculator →

Administration

Route
IM or Parabulbar injection
Timing
Once daily course.
Fasting Required?
No — food timing not critical

Expected Timeline

Week 2-4
Improvement in visual acuity and visual field parameters in diabetic retinopathy.

Who Is It For?

Diabetic Retinopathy / Glaucoma

Moderate

Registered medicine in Russia for degenerative eye diseases.

Reconstitution Example

Vial
5 mg
Water
1 mL
Concentration
5 mg/mL
Per Unit (100u syringe)
50 mcg
Dose of 5000 mcg = 100 units on a 100-unit insulin syringe

Safety & Considerations

Registered pharmaceutical in Russia. Clinical supervision required. Parabulbar injection must be performed by a specialist.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Interactions & Contraindications

Parabulbar injection requires trained ophthalmologist. No reported drug interactions with standard optic medications.

Synergies & Common Stacks

Retinalamin (injectable extract) + Visoluten (oral capsule) = comprehensive eye health protocol combining systemic and targeted delivery.

Retinalamin + Normoftal target different aspects of ocular tissue health.

Dosing Quick Reference

Retinalamin— Dosing Guide
Dose Range
5 mg IM or parabulbar injection
Half-Life
~2 hours
Frequency
1× daily for 10 days
Route
Subcutaneous
5 mg vial
💧 1 mL BAC water📐 5 mg/mL concentration💉 50 mcg/unit (100u syringe)
Khavinson Bioregulatorcalcmypeptide.com

Frequently Asked Questions

Is Retinalamin the same as Visoluten?
Visoluten is the oral dietary supplement (Cytomax) version for preventive eye health. Retinalamin is the sterile, injectable pharmaceutical medicine designed for treating active diagnosed ocular diseases.

References

  1. Astakhov YS et al. "Retinoprotective effect of Retinalamin in diabetic retinopathy".” Vestnik Oftalmologii (2008). PMID: 19140417
Recommended SourceOral Bioregulator

Get Retinalamin from Vita-Stream — the comprehensive distributor for authentic Khavinson bioregulators. Oral capsules, no injections required.

Affiliate link · Full review